Guselkumab significantly reduced symptoms and inhibited joint damage in active PsA over 48 weeks in the APEX study. The trial involved biologic-naïve patients with inadequate responses to standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback